Shots:
- The P-III study evaluates the safety and efficacy of Ultomiris vs PBO in 175 adults in a ratio (1:1) with gMG with no prior treatment with a complement inhibitor medicine across North America, EU, Asia-Pacific, and Japan for 26 wks.
- The study met its 1EPs of change from baseline in MG-ADL total score @26wks. & demonstrated efficacy as early as 1wks. that sustained for 52 wks. Additionally, the therapy was well tolerated with a consistent safety profile with that seen in P-III studies for PNH & aHUS
- The company plans to make regulatory filings in the US, EU & Japan in late 2021 or early 2022, based on P-III results
Click here to read full press release/ article | Ref: Alexion | Image: Anticorr
The post Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study for Generalized Myasthenia Gravis first appeared on PharmaShots.
